HSK44459
Small molecule
Evidence outlook · registrational
Idiopathic Pulmonary Fibrosis: registrational trial registered, not yet recruiting
Its supporting mid-stage studies have completed. Registrational readout expected around 2028-04-05.
Also in development:Atopic Dermatitis · Phase 2Psoriasis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07519070 NCT07519070 · Idiopathic Pulmonary Fibrosis Registry: NCT07519070 | 3 | Change in FVC from baseline at Week 52 2028-04-05 | In progress: results expected 5 Apr 2028 | not yet graded | link ↗ |
View 1 more trial
PPF NCT07503587 · Idiopathic Pulmonary Fibrosis Registry: NCT07503587 | 3 | The change from baseline in forced vital capacity (FVC) at week 52 (day 1 and week 52) 2028-12-30 | In progress: results expected 30 Dec 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other PDE4B drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Idiopathic Pulmonary Fibrosis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HSK44459: this drug | Phase 3 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| Nerandomilast (Jascayd) | Approved | Small molecule | PDE4B | Reliable signal | NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) | |
| Nintedanib (Ofev) | Approved | Small molecule | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) | Partial signal | NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results). NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results). | |
| Pirfenidone (Esbriet) | Approved | Small molecule | Pyridone | Reliable signal | NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results). | |
| Treprostinil (Tyvaso DPI) | Approved(overall) | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-722 | Phase 1(overall) | Small molecule | LPAR1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziritaxestat | Discontinued | Small molecule | autotaxin (ENPP2) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HSK44459 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.